NVCT / U.S. IPO Weekly Recap: The February IPO Market Kicks Off With 2 Biotechs

The heavy selling pressure might have exhausted for Nuvectis Pharma, Inc. (NVCT) as it is technically in oversold territory now. In addition to this t more_horizontal

Fort Lee, NJ, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutica more_horizontal

Nuvectis is developing precision medicines for cancer patients, with lead asset NXP800 targeting ARID1a-mutated ovarian cancer. Preclinical trials hav more_horizontal

Nuvectis Pharma, Inc. (NVCT) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound more_horizontal

The average of price targets set by Wall Street analysts indicates a potential upside of 29.4% in Nuvectis Pharma, Inc. (NVCT). While the effectivenes more_horizontal

FORT LEE, NJ, April 27, 2023 (GLOBE NEWSWIRE) -- In the news release, Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conf more_horizontal

FORT LEE, NJ, May 20, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the devel more_horizontal

Biotech stocks aren't a sure thing, but one good sign is insiders buying up shares. These three all offer that enticing feature. more_horizontal